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10 Abstract
11 Purpose of Review Spurred by the successful application of
12 structural vaccinology to other challenging bacterial and viral
13 pathogens, we review the possibility of exploiting 3D struc-
14 ture computational-based recombinant antigen engineering
15 strategies for the development of a protective melioidosis
16 vaccine.
17 Recent Findings Structure-based epitope design approaches
18 in the melioidosis field are preliminary and applied essentially
19 by one research network. By combining Burkholderia
20 pseudomallei antigen 3D structures and in silico epitope dis-
21 covery methods, a panel of synthetic epitope peptides were
22 designed and tested for their B and T cell stimulatory activi-
23 ties. Several peptides were found to be serodiagnostic for B.
24 pseudomallei infection and two elicited bactericidal
25 antibodies.
26 Summary A significant amount of B. pseudomallei antigen
27 structures, epitopes, and immunological data is available.
28 Future challenges will be to test all available B. pseudomallei
29 epitopes, focusing on combing multiple B/Tcell epitopes onto
30a single scaffold to generate components, stimulating both
31arms of the immune system.
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34Introduction Q2
35Melioidosis is a potentially fatal disease caused by the soil-
36borne, intracellular Gram-negative bacillus Burkholderia
37pseudomallei, endemic in the tropical and subtropical re-
38gions of the world [1]. Proper diagnostic tests are unavail-
39able, and accordingly, melioidosis is often misdiagnosed
40and/or underreported, leading to the global distribution of
41melioidosis being extensively underestimated [2•]. The
42worst affected areas are North Thailand and North
43Australia where mortality rates can reach 50 and 19%, re-
44spectively [3]. There are a number of risk factors that pre-
45dispose individuals to B. pseudomallei infection, including
46diabetes, alcoholism, and the presence of chronic lung and/
47or liver pathologies. The bacterium enters the body via in-
48halation, ingestion, and percutaneous inoculation and
49causes diverse clinical outcomes including pneumonia,
50multiple abscesses, and fatal septicemia [2•, 4].
51B. pseudomallei is resistant to all major antibiotic classes;
52therefore, empirically administered antibiotics given to pa-
53tients in the absence of proper diagnosis are ineffective [5,
546]. Such diagnostic and therapeutic challenges, coupled to
55its classification as a Tier 1 select agent by the Centers for
56Disease Control and Prevention, have spurred research efforts
57directed at the discovery and development of a melioidosis
58vaccine and improved diagnostic tools [7].
59In this context, structure-based antigen engineering is
60evolving as a modern-day strategy to develop improved
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61 vaccine components, and it is predicted by experts in the field
62 to deliver future vaccines targeting complicated pathogens
63 such as HIV [8••]. This report reviews the possibility of ap-
64 plying structural vaccinology (SV) approaches for the devel-
65 opment of a melioidosis vaccine and outlines some initial SV
66 studies made on specific B. pseudomallei antigens.
67 Human Immune Responses to B. pseudomallei
68 Due to its intracellular nature, B. pseudomallei invades and
69 replicates inside both phagocytic and non-phagocytic cells
70 and can do so for prolonged periods. After it is taken up by
71 the cell vacuole, it can escape and replicate in the host cytosol.
72 In fact, a key factor that renders treatment of melioidosis chal-
73 lenging is the ability of B. pseudomallei to persist, eventually
74 leading to chronic disease. For these reasons, a protective
75 melioidosis vaccine must contain antigenic components that
76 induce both cell-mediated and humoral responses of the hu-
77 man immune system [9].
78 The innate immune system plays a vital and primary role in
79 clearance of Burkholderia from the body following host inva-
80 sion. A number of key cell types are activated in response to
81 infection, e.g., macrophages and natural killer cells [10].
82 When replication is not prevented, chronic infection pro-
83 gresses, and the role of CD4+ T cells is critical for long-term
84 infection control [11].
85 The adaptive immune response to B. pseudomallei infec-
86 tion is less understood. Melioidosis patients with acute phase
87 infections exhibit high antibody titers associated to three IgG
88 isotypes, confirming the importance of the antibody response
89 [12]. A number of vaccine candidates have been tested for
90 their capacity to induce immune protection against challenge
91 with B. pseudomallei in vivo and will be discussed in the
92 following section.
93 Current Burkholderia Vaccine Research
94 Tested vaccine candidates range from live-attenuated forms of
95 the bacterium, to recombinant protein antigens and to DNA
96 and polysaccharide subunits; however, a neutralizing vaccine
97 has yet to be formulated [13••].
98 Mycobacterium tuberculosis and B. pseudomallei have
99 shared characteristics e.g., both are intracellular, they can per-
100 sist for years and they have similar histological and clinical
101 profiles. Immunization with chronic and acute phase M.
102 tuberculosis antigens expressed on the same polypeptide led
103 to increased immune protection in mice challenged with in-
104 fection, and human clinical trials are in progress [14–16]. This
105 led Champion et al. to conduct a similar study on B.
106 pseudomallei. Three chronic phase B. pseudomallei antigens
107 (BPSL3369, BPSL1897, and BPSL2287) and BPSL2765,
108due to its link to non-recurrent incidences of melioidosis, were
109used to immunize mice achieving significant immune protec-
110tion in comparison with the most protective vaccine candi-
111dates tested to date, namely the LolC recombinant protein
112and capsular polysaccharides [17••, 18, 19].
113Structural Vaccinology
114The 3D architecture of antigens can reveal the structures, the
115(a)polar and electrostatic surfaces recognized by neutralizing
116antibodies, and can guide the design of improved immuno-
117gens [20, 21]. Introducing structural modifications can ad-
118dress both practical and immunological challenges. For exam-
119ple, as only epitope containing portions of an antigen are re-
120quired to induce an immune response, 3D structure informa-
121tion can be used to focus on smaller immunogenic substruc-
122tures of an antigen, thus facilitating its production (e.g., when
123the production of large multi-domain antigens is problematic).
124With respect to substructure size, the smallest example is the
125translation of antigen portions into relatively small peptides, a
126strategy that potentially brings a considerable potential over
127traditional vaccination approaches [22]. Also, by identifying
128antigenic domains that specifically elicit protective immunity,
129rational antigen engineering based on structural consider-
130ations, can be driven. For example, when neutralizing epitope
131conformations are t rans ient , or hidden by more
132immunodominant yet non-protective epitopes, attempts may
133be made to block or improve the presentation of neutralizing
134conformations. Epitope grafting, peptide cyclization, and sta-
135pling techniques are some useful and successful approaches
136that have been applied in this context [23–28].
137Computationally Assisted Antigen (re)Design
138The prerequisites for structure-based antigen engineering, also
139termed structural vaccinology, is the 3D antigen structure,
140obtained via experimental methods (X-ray crystallography or
141nuclear magnetic resonance [NMR]), or through in silico
142methods (homology modeling) when suitable structural ho-
143mologs are available in the Protein Data Bank (PDB; www.
144rcsb.org), coupled to knowledge of epitope region locations.
145There have been significant advances in computational
146biology and the development of depositories hoarding large
147amounts of epitope data. Consequently, in addition to
148experimental determination, epitope sequence information
149may be accurately predicted using more rapid and
150economical sequence-based and (to a lesser extent) struc-
151ture-based, in silico epitope prediction methods [29–32].
152When knowledge of both epitope sequence and 3D conforma-
153tion is known, structure-based antigen engineering may thus
154proceed to further vaccine design.
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155 SVApproaches Applied to B. pseudomallei Antigens
156 Examples of SVapplied to Burkholderia antigens are limited
157 and focus on the discovery and design of antigenic epitopes as
158 an alternative to the full antigen, using structure-based in silico
159 epitope predictions and design. Target antigens belong to a list
160 of 49 proteins found to be serodiagnostic for B. pseudomallei
161 infection, based on the results of a protein microarray study
162 presenting over 1000 in silico-predicted surface antigens, and
163 on a subsequent study involving convalescent sera that report-
164 ed 27 proteins that are specifically recognized by recovery
165 IgGs [18, 33••].
166 B. pseudomallei SV studies involved the use of two 3D
167 structure-based in silico epitope prediction methods called
168 matrix of local coupling energies (MLCE) and electrostatic
169 desolvation profiles (EDP) [34, 35]. These twomethods detect
170 different physico-chemical properties that are characteristic of
171 epitopes; therefore, epitope prediction precision is improved
172 by selecting consensus sequences.
173 MLCE specifically pinpoints antigenic residues that are
174 located in dynamic and conformationally flexible regions of
175 the antigen by identifying solvent-accessible residues that are
176 less energetically coupled with the rest of the protein, e.g., that
177 are not involved in stabilizing interactions within the protein
178 fold. In other words, these regions can adapt to bind a partner,
179 specifically an antibody, with minimal energetic expense and
180 can tolerate well-conformational changes determined by anti-
181 body recognition [35]. In contrast, EDP identifies generic
182 protein-protein interaction interfaces by looking at surface
183 cavities where desolvation would be energetically favored up-
184 on antibody binding [34]. Both methods were successfully
185 tested on a Chlamydia antigen and led to the design of a
186 cross-species immunogenic domain [36].
187 Peptidoglycan-Associated Lipoprotein
188 Peptidoglycan-associated lipoprotein (Pal) (BPSL2765) is a
189 seroreactive recovery antigen, recognized by IgGs from pa-
190 tients who have had one episode of melioidosis in comparison
191 with those with recurrent melioidosis, suggesting a role in
192 conferring immune protection [18]. Accordingly, Pal was
193 shown to offer limited protection in a mouse immunization
194 study [17••, 18, 37], and together with two other antigens
195 (FliC and the N-terminal domain of seroreactive antigen
196 BPSS1599) was found to stimulate human memory T and B
197 cells in a humanized melioidosis mouse model [38•].
198 MLCE and EDP were combined and applied to the Pal
199 crystal structure (3D structure coordinates are available from
200 the PDB under entry code 4B5C) and led to the identification
201 of a highly immunogenic epitope (Pal3) that, when adminis-
202 tered to rabbits in peptide form, elicited antibodies that were
203 bactericidal in vitro against B. pseudomallei [39••]. In
204addition, Pal3 clearly discriminated between melioidosis
205healthy seronegative, healthy seropositive, and convalescent
206patient subgroups. The full-length recombinant Pal antigen
207did not exhibit such properties, underlining the successful out-
208come of this SV approach and the potential of generating a
209better immunogen by “extracting” epitope regions from the
210initial antigen and producing them separately (Fig. 1). Future
211applications of the Pal3 epitope may be for both vaccine and
212diagnostic purposes [39••].
213Oligopeptide Binding Protein
214Oligopeptide-binding protein (OppA) (BPSS2141) is a mem-
215ber of the ATP-binding cassette (ABC) transporter family,
216whose members are known immunogens in Gram-negative
217bacteria in general. OppA, together with two other ATP-
218binding cassette system proteins, PotF and LolC, were shown
219to induce both humoral and cell-mediated immune responses
220in BALB/c mice challenged with B. pseudomallei [40]. A SV
221study analogous to that carried out on Pal was applied to the
222OppA crystal structure (PDB entry 3ZS6) [41]. Given the
223structural organization of the OppA fold into two lobes, a
224computational fragmentation into sub-domains prior to pre-
225dictions using MLCE resulted in improved prediction accura-
226cy. All three OppA epitopes were confirmed to be B cell
227epitopes, as judged by their immune sera reactivity when syn-
228thesized in peptide form [41]. One peptide, in particular, clear-
229ly distinguished between healthy seronegative, healthy sero-
230positive, and convalescent melioidosis patient groups, imply-
231ing a possible role in diagnosis.
232Flagellin and the Flagellar Hook-Associated Protein
233The flagellar hook-associated protein flagellar hook-
234associated protein (FlgK) (BPSL0280) and the flagellar sub-
235unit flagellin (FliC) (BPSL3319) are two B. pseudomallei an-
236tigens that displayed the highest seroreactivity toward im-
237mune sera from melioidosis recovery patients [18].
238Antibodies raised against FliC proteins from diverse B.
239pseudomallei species were shown to offer passive protection
240in vivo [42]. Based on these findings, both antigens were
241deemed good SV targets. In this case and considering recent
242improvement in predictions made by MLCE alone, EDP was
243excluded from epitope predictions applied to the crystal struc-
244tures of FliC (PDB entry 4CFI) and FlgK (PDB entry 4UT1);
245for FliC, sequence-based epitope predictions were also carried
246out [43, 44]. Relevant to melioidosis, two out of three FliC
247epitope peptides were found to be joint good T and B cell
248epitopes [44]. With regard to FlgK, epitopes were found to
249be clustered to discrete domains that may represent good
250starting points for the design of immunogenic domains [43].
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251 BPSL1050
252 The NMR structure of seroreactive antigen of unknown func-
253 tion BPSL1050 (PDB entry 2MPE) was used for the applica-
254 tion of MLCE and EDP methods, and the two designed epi-
255 tope peptides successfully induced antibodies with B.
256 pseudomallei agglutination activities that were superior to
257 those induced by antibodies raised against recombinant
258 BPSL1050 [45].
259 Future Therapeutic Applications for Discovered B.
260 pseudomallei Epitopes
261 B. pseudomallei epitope peptides may serve as vaccine com-
262 ponents (Fig. 1). Although, peptides are poorly immunogenic
263 per se, they can be easily conjugated to other chemically
264diverse immunogens, e.g., individual proteins or carbohy-
265drates, and their stability in plasma can be improved via di-
266verse engineering/chemical modification strategies [46].
267Examples of protein carriers include tetanus and diptheria tox-
268oids, known per se to induce an immune response [47••, 48].
269One means of improving their immunogenicity is to present
270them in vessels that prime the immune response. One such
271delivery vessel that is gaining attention in the field is outer
272membrane vesicles (OMVs) derived from the pinching off of
273portions of the outer membrane (OM) of Gram-negative bac-
274teria. OMVs contain molecules that encounter the key players
275of the host immune response, e.g., membrane and periplasmic
276proteins and membrane polysaccharides, which may act as
277adjuvants of the immune response. OMVs isolated from B.
278pseudomallei 1026b have been shown to provide good pro-
279tection in non-human primates, although they did not
280completely neutralize the bacteria [49]. Decoration of OMVs
Fig. 1 The melioidosisQ3 vaccine development puzzle. Pictorial
representation of the state-of-the-art for structure-based antigen/epitope
discovery and engineering, targeting B. pseudomallei (Bp) seroreactive
antigens of known 3D structure. The figure illustrates how diverse
advances in diverse scientific areas (structural biology, computational
biology, chemistry, and immunology), must come together toward a
common aim—melioidosis vaccine development—and summarizes the
progress made to date. 1. 3D Bp antigen structures are used for epitope
discovery; 2. Epitope sequence and structure data are obtained via in
silico and in vitro methods; 3. Chemistry is used to block epitopes in
the desired conformation; 4. Epitopes may be combined and presented
on vaccine delivery vessels, such as outer membrane vesicles (OMVs)
and nanoparticles (e.g., gold); 5. Structure-based epitope grafting may be
used as an alternative to combine multiple antigens, generating “super”
antigens; 6. B cell epitopes may be presented in microarray format for
immunodiagnostic purposes to detect B. pseudomallei infection and
infection stage; 7. In vitro immunological data is essential to determine
effective B cell and T cell stimulatory activities. The missing piece of the
puzzle regards in vivo protection studies with B. pseudomallei epitopes,
which are still lagging behind
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281 with B. pseudomallei antigens or epitopes has not yet been
282 exploited; however, the availability of several B. pseudomallei
283 epitopes, with both B and T cell stimulatory activities, and the
284 intrinsic immunogenicity of B. pseudomallei OMVs suggest
285 this to be a vital avenue to pursue in the immediate future.
286 Multiple-Epitope Presentation
287 A subunit melioidosis vaccine represents a safer alternative to
288 a live-attenuated vaccine and efforts should focus on formu-
289 lating a multivalent vaccine containing several immunogenic
290 epitopes that lead to improved immune responses [50•]. In this
291 context, once the sequence and 3D structure of epitopes are
292 known, SVmethods can be used to engineer multiple epitopes
293 for presentation on a single protein scaffold. Structure-based
294 antigen engineering, such as epitope grafting, can be used to
295 transplant neutralizing epitopes from one antigen onto a struc-
296 turally homologous region of a diverse protein scaffold
297 [24–27]. When the protein scaffold itself is a full-length pro-
298 tein antigen, this can result in multiple-epitope presentation
299 that can lead to accentuated immune responses. With regard
300 to B. pseudomallei, in light of promising subunit protection
301 studies with three chronic phase antigens and BPSL2765,
302 combining T and B cell B. pseudomallei epitopes on the same
303 scaffold could prove an ideal strategy to contemporarily in-
304 duce both cell and antibody immune responses; however, no
305 studies of this type have been reported to date.
306 Future Diagnostic Applications for Discovered B.
307 pseudomallei Epitopes
308 Current B. pseudomallei diagnostic tests are based on
309 lengthy bacterial culture procedures that exhibit poor sen-
310 sitivity and specificity, leading to many melioidosis cases
311 being unreported and to disease progression. Potential bio-
312 markers include O-polysaccharide (OPS) and hemolysin
313 co-regulated protein 1 (Hcp1) [51]. A recent report cites
314 preliminary data on the use of a monoclonal antibody-
315 based immunofluorescent assay (IFA) that recognizes a B.
316 pseudomallei exopolysaccharide [52].
317 A more rapid method is the indirect hemagglutination
318 assay (IHA) used to diagnose infections in Australia by
319 measuring antibody titers to three lipopolysaccharide
320 (LPS) types; however, its sensitivity is poor and is as low
321 as 25% in North Eastern Thai populations, where compli-
322 cations are encountered due to high antibody titers in the
323 local population, resulting from natural exposure to the
324 non-pathogenic B. thailandensis species that co-habits with
325 B. pseudomallei [53, 54].
326 The key to developing a serological-based test is the iden-
327 tification of specific biomarkers that do not lead to ambiguous
328diagnosis. In this context, the antigens identified in the protein
329microarray studies carried out by Felgner et al. and
330Suwannasaen et al. represent serodiagnostic antigens for fur-
331ther evaluation as biomarkers [18].
332There are over 40 highly conserved species pertaining to
333the Burkholderia genus. Other members that are pathogenic
334include B. mallei, responsible for glanders in horses and other
335solipeds, and B. cenocepacia, which causes opportunistic in-
336fections in cystic fibrosis (CF) patients. Peptide-based immu-
337nodiagnostic tests are advantageous, as peptides are easy to
338produce and chemical modifications may be easily introduced
339to constrain peptide conformation, thus presenting peptides in
340microarrays in conformations that are optimally recognized by
341serum IgGs (Fig. 1).
342The possibility of using B. pseudomallei synthetic pep-
343tide epitopes to diagnose B. cenocepacia infections in CF
344patients was confirmed by a recent study [55••]. Silica
345chips were used to present the synthetic epitope peptides
346from Pal, FliC, OppA, and BPSL1050 [55••]. All B.
347pseudomallei peptides were seroreactive against immune
348sera form CF patients harboring B. cenocepacia infections.
349Moreover, the sensitivity of this microarray was found to
350be excellent, and the same peptides were not recognized by
351IgGs from healthy controls or CF patients with different
352bacterial infections, such as Pseudomonas aeruginosa
353[55••]. For peptide-based immunodiagnostics, the exten-
354sive natural variability of Burkholderia species must be
355taken into consideration when selecting cross-reactive an-
356t igens. Genome sequence information for diverse
357Burkholderia species should be screened, and selected can-
358didates should belong to the conserved core genome.
359In a separate study, the effect of peptide conforma-
360tional flexibility was evaluated relative to immune sera
361recognition and the elicitation of bactericidal antibodies.
362The more rigid α-helical conformation of Pal3,
363constrained by introducing a 1,4-disubstituted-1,2,3-tri-
364azole chemical staple could discriminate better between
365diverse melioidosis patient serotypes than the linear pep-
366tide [56•]. In contrast, the constrained peptide elicited a
367more limited repertoire of antibodies with reduced bac-
368tericidal properties in comparison to the linear epitope
369peptide, suggesting that peptide epitope design strategies
370should evaluate peptide conformation and dynamics, rel-
371ative to its desired application [56•].
372Conclusion
373Based on the results, data, and recent developments that we
374review in this paper, we conclude that the full integration
375of computer-based approaches with structural biology is
376coming of age, and that the next few years will witness a
377huge increase in the use of designed biomolecular agents
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378 for immunological applications. The increasing availabili-
379 ty of 3D B. pseudomallei antigen structures solved by X-
380 ray crystallography or NMR, and the increasing accuracy
381 o f i n s i l i c o homo l ogy mode l s , t o g e t h e r w i t h
382 computational-based epitope prediction tools raises the
383 possibility of rapidly generating large libraries of immuno-
384 reactive peptides for immunological testing and hence, di-
385 agnostic and therapeutic potential. There are 11 structures
386 of known seroreactive antigens (identified by Felgner et al.
387 [33••]) deposited in the PDB; structural homologs with
388 higher than 30% sequence identity to 18 B. pseudomallei
389 antigens are available, together with two additional struc-
390 ture homologs for chronic phase antigens BPSL2287 and
391 BPSL3369 tested in the most successful protection study
392 carried out to date [17••]. We can also consider 3D struc-
393 tures pertaining to other Burkholderia species, such as
394 B. mallei and B. cenocepacia. Such wealth of structural
395 data can be valuable for designing improved immunogens
396 when complemented with in vitro and in vivo immunolog-
397 ical studies.
398 With regard to melioidosis diagnostics, initial find-
399 ings render the notion of using a single peptide-based
400 immunodiagnostic test to diagnose diverse Burkholderia
401 infections a reality. Incorporating multiple epitopes from
402 diverse bacteria raises the possibility of screening mul-
403 tiple bacterial infections in one shot.
404 SV applications to vaccine design and production
405 have been so far limited, despite initial promising re-
406 sults reported for protein antigens from diverse patho-
407 gens such as the respiratory syncytial virus, Neisseria
408 meningitidis serotype B, and Haemophilus influenzae
409 [57]. There is no reason to suggest that a melioidosis
410 vaccine may not be achieved using analogous ap-
411 proaches; however, we believe that a large multidisci-
412 plinary research effort is required; in vivo studies cur-
413 rently represent one of the missing pieces of the puzzle
414 and are essential to understand whether any of the B.
415 pseudomallei epitopes identified to date display effec-
416 tive protection in a vaccine formulation (Fig. 1).
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